AR061989A1 - Combinacion de peroxido de adapaleno y benzoilo para el tratamiento de lesiones de acne - Google Patents

Combinacion de peroxido de adapaleno y benzoilo para el tratamiento de lesiones de acne

Info

Publication number
AR061989A1
AR061989A1 ARP070103115A ARP070103115A AR061989A1 AR 061989 A1 AR061989 A1 AR 061989A1 AR P070103115 A ARP070103115 A AR P070103115A AR P070103115 A ARP070103115 A AR P070103115A AR 061989 A1 AR061989 A1 AR 061989A1
Authority
AR
Argentina
Prior art keywords
adapalene
combination
treatment
bpo
acne
Prior art date
Application number
ARP070103115A
Other languages
English (en)
Inventor
Loesche Christian
Gross Denis
Abou-Chacra Vernet Marie
Line-Poncet Michel
Original Assignee
Galderma Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37763873&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR061989(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Galderma Res & Dev filed Critical Galderma Res & Dev
Publication of AR061989A1 publication Critical patent/AR061989A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Abstract

La presente se refiere al uso de adapaleno o una sal farmacéuticamente aceptable de éste, para la fabricación de una composición farmacéutica para reducir el número de lesiones del acné, a través de la aplicación tópica diaria, en combinación o asociación con peróxido de benzoilo (BPO). El tratamiento recomendado puede presentar la forma de una composición farmacéutica que combina adapaleno y BPO, o una aplicación concomitante de dos composiciones farmacéuticas, una que comprende adapaleno y la otra que comprende BPO.
ARP070103115A 2006-07-13 2007-07-13 Combinacion de peroxido de adapaleno y benzoilo para el tratamiento de lesiones de acne AR061989A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0652968A FR2903603B1 (fr) 2006-07-13 2006-07-13 Combinaison d'adapalene et de peroxyde de benzole dans le traitement de l'acne

Publications (1)

Publication Number Publication Date
AR061989A1 true AR061989A1 (es) 2008-08-10

Family

ID=37763873

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070103115A AR061989A1 (es) 2006-07-13 2007-07-13 Combinacion de peroxido de adapaleno y benzoilo para el tratamiento de lesiones de acne

Country Status (23)

Country Link
US (6) US8129362B2 (es)
EP (2) EP2046318B1 (es)
JP (3) JP2009542779A (es)
KR (3) KR20150003917A (es)
CN (1) CN101541320B (es)
AR (1) AR061989A1 (es)
AU (1) AU2007274288B2 (es)
BR (1) BRPI0713182A8 (es)
CA (1) CA2656456A1 (es)
CO (1) CO6150136A2 (es)
CY (1) CY1121398T1 (es)
DK (2) DK2450035T3 (es)
ES (2) ES2423951T3 (es)
FR (1) FR2903603B1 (es)
HU (1) HUE043502T2 (es)
LT (1) LT2450035T (es)
MX (1) MX2009000319A (es)
PL (2) PL2450035T3 (es)
PT (2) PT2046318E (es)
RU (3) RU2009104949A (es)
SI (2) SI2046318T1 (es)
TR (1) TR201819658T4 (es)
WO (1) WO2008006888A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7820186B2 (en) 2001-12-21 2010-10-26 Galderma Research & Development Gel composition for once-daily treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt
FR2910320B1 (fr) 2006-12-21 2009-02-13 Galderma Res & Dev S N C Snc Emulsion comprenant au moins un retinoide et du peroxyde de benzole
FR2910321B1 (fr) 2006-12-21 2009-07-10 Galderma Res & Dev S N C Snc Gel creme comprenant au moins un retinoide et du peroxyde de benzole
DK2114392T3 (en) * 2007-01-30 2015-09-07 Galderma Res & Dev Applied adapalene and benzoyl peroxide FOR LONG-TERM TREATMENT OF ACNE VULGARIS
CN105287484A (zh) * 2007-11-30 2016-02-03 盖尔德马研究及发展公司 含有萘甲酸衍生物、过氧化苯甲酰和成膜剂的组合物
KR20110021888A (ko) * 2008-05-16 2011-03-04 갈데르마 리써어치 앤드 디벨로프먼트 여드름 관련 질환을 치료하기 위한 치료 요법
WO2011098391A1 (en) * 2010-02-09 2011-08-18 Galderma Research & Development A dermatological composition comprising a combination of adapalene and benzoyl peroxide for the treatment of acne in non- caucasian population with decrease of post- inflammatory hyperpigmentation
WO2011135090A1 (en) * 2010-04-29 2011-11-03 Galderma Research & Development Method for treating scars with adapalene 0.3%
FR2969491B1 (fr) * 2010-12-23 2013-07-12 Galderma Res & Dev Mousses dermatologiques obtenues a partir d'un gel ou d'une suspension contenant une combinaison d'adapalene et de bpo
US8563535B2 (en) * 2011-03-29 2013-10-22 Kamal Mehta Combination composition comprising benzoyl peroxide and adapalene
EP2854791A1 (en) * 2012-05-25 2015-04-08 Galderma Research & Development Treatment of preadolescent moderate acne vulgaris
HUE035940T2 (en) * 2012-11-20 2018-05-28 Allergan Inc Topical dapson and dapson / adapalen formulations and application procedures
WO2015150332A1 (en) * 2014-04-01 2015-10-08 Galderma Research & Development Combination of adapalene and benzoyl peroxide for treating acne scars
US20170216231A1 (en) 2014-07-25 2017-08-03 Galderma Research & Development Combination of adapalene and benzoyl peroxide for the treatment of severe acne
CN108024980A (zh) * 2015-08-20 2018-05-11 索尔-格尔科技有限公司 包含过氧化苯甲酰和阿达帕林的用于局部施用的组合物
JP6679299B2 (ja) * 2015-12-21 2020-04-15 第一三共ヘルスケア株式会社 ニキビ治療用外用医薬組成物
WO2018080284A1 (ko) * 2016-10-31 2018-05-03 (주)동구바이오제약 여드름 치료용 약물의 생체이용률을 증진시키는 약학적 조성물
KR101986177B1 (ko) * 2016-10-31 2019-06-05 (주)동구바이오제약 여드름 치료용 약물의 생체이용률을 증진시키는 약학적 조성물
MX2017003003A (es) * 2017-03-08 2018-09-07 Centro Int De Cosmiatria S A P I De C V Composición y método para el tratamiento tópico del acné severo.
RU2019134342A (ru) * 2017-03-30 2021-04-28 Сайнтелл, Ллк Способ лечения и предупреждения инфекций

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW203552B (en) * 1992-02-18 1993-04-11 J Baroody Lloyd Compositions of clindamycin and benzoyl peroxide for acne treatment
FR2727609B1 (fr) 1994-12-06 1997-01-10 Oreal Ensemble de distribution pour l'application d'un produit de consistance liquide a pateuse
FR2775566B1 (fr) 1998-03-03 2000-05-12 Oreal Cupule porte raisin et ensemble de conditionnement pour un produit de maquillage la comportant
US6559189B2 (en) * 1999-04-28 2003-05-06 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
FR2806273B1 (fr) 2000-03-16 2002-10-04 Oreal Dispositif de conditionnement et d'application d'un produit cosmetique ou de soin
FR2833841B1 (fr) * 2001-12-21 2005-07-22 Galderma Res & Dev Gel comprenant au moins un retinoide et du peroxyde de benzoyle
US7820186B2 (en) * 2001-12-21 2010-10-26 Galderma Research & Development Gel composition for once-daily treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt
FR2837101B1 (fr) 2002-03-12 2004-07-02 Galderma Res & Dev Utilisation de l'acide 6-[1-adamantyl)-4-methoxyphenyl]-2- naphthoique pour le traitement de desordres dermatologiques
GB0301577D0 (en) * 2003-01-23 2003-02-26 Edko Pazarlama Tanitim Ltd Sti Topical pharmaceutical and/or cosmetic dispense systems
EP1648491A1 (en) 2003-07-23 2006-04-26 XOMA Technology Ltd. Use of xmp-629 for the treatment of acne
US20050239723A1 (en) 2004-04-27 2005-10-27 Amin Avinash N Compositions and methods useful for treatment of acne
US20060128808A1 (en) 2004-10-20 2006-06-15 Galderma Research & Development, S.N.C. Method of using adapalene in acne maintenance therapy
AR054805A1 (es) * 2005-06-29 2007-07-18 Stiefel Laboratories Composiciones topicas para el tratamiento de la piel
FR2901139B1 (fr) 2006-05-17 2009-03-20 Galderma Res & Dev S N C Snc Compositions comprenant au moins un derive de l'acide naphtoique et du peroxyde de benzoyle, leurs procedes de preparation, et leurs utilisations

Also Published As

Publication number Publication date
CA2656456A1 (en) 2008-01-17
PL2046318T3 (pl) 2013-12-31
BRPI0713182A8 (pt) 2018-01-02
SI2046318T1 (sl) 2013-11-29
FR2903603B1 (fr) 2009-03-20
ES2423951T3 (es) 2013-09-25
US20120059063A1 (en) 2012-03-08
US20170202803A1 (en) 2017-07-20
JP2009542779A (ja) 2009-12-03
RU2012136952A (ru) 2014-03-10
DK2450035T3 (en) 2019-02-25
US8785420B2 (en) 2014-07-22
PL2450035T3 (pl) 2019-04-30
RU2009104949A (ru) 2010-08-20
EP2450035A1 (en) 2012-05-09
AU2007274288A1 (en) 2008-01-17
BRPI0713182A2 (pt) 2012-04-17
PT2450035T (pt) 2019-02-26
AU2007274288B2 (en) 2013-05-02
EP2450035B1 (en) 2018-11-21
KR20160120352A (ko) 2016-10-17
US20120115947A1 (en) 2012-05-10
CN101541320A (zh) 2009-09-23
US8071644B2 (en) 2011-12-06
FR2903603A1 (fr) 2008-01-18
JP2014040481A (ja) 2014-03-06
HUE043502T2 (hu) 2019-08-28
WO2008006888A1 (en) 2008-01-17
KR20090028764A (ko) 2009-03-19
KR20150003917A (ko) 2015-01-09
DK2046318T3 (da) 2013-08-05
CY1121398T1 (el) 2020-05-29
US20090253788A1 (en) 2009-10-08
CN101541320B (zh) 2014-04-09
RU2012144414A (ru) 2014-04-27
TR201819658T4 (tr) 2019-01-21
SI2450035T1 (sl) 2019-03-29
MX2009000319A (es) 2009-03-12
LT2450035T (lt) 2019-01-25
PT2046318E (pt) 2013-09-04
EP2046318A1 (en) 2009-04-15
JP2016029094A (ja) 2016-03-03
ES2703505T3 (es) 2019-03-11
US20140296340A1 (en) 2014-10-02
CO6150136A2 (es) 2010-04-20
US8129362B2 (en) 2012-03-06
US20080033047A1 (en) 2008-02-07
EP2046318B1 (en) 2013-06-05

Similar Documents

Publication Publication Date Title
AR061989A1 (es) Combinacion de peroxido de adapaleno y benzoilo para el tratamiento de lesiones de acne
AR115939A2 (es) Composición que contiene palmitoil-etanolamida ultra-micronizada
AR124134A2 (es) Formulación de uso tópico para un inhibidor de jak
AR054805A1 (es) Composiciones topicas para el tratamiento de la piel
CL2013001136A1 (es) Un agente inhibitorio de la fosfodiesterasa 7 (pde7) para ser usado en el tratamiento o la reduccion de la posibilidad de una adiccion; y composicion farmaceutica, forma de dosificacion unitaria y kit farmaceutico que incluyen al inhibidor de fosfodiesterasa 7 (pde7) y un agente terapeutico adicional.
CL2007001724A1 (es) Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
AR068565A1 (es) Composiciones para el tratamiento del cabello
PA8809601A1 (es) Combinación anti-retroviral
CL2007001752A1 (es) Compuesto 4-[5(2-amino-etansulfonil)-isoquinolin-7-il]-fenolo una sal farmaceuticamente aceptable o un hidrato o la sal del mismo;composicion farmaceutica que comprende a dicho compuesto,composicion farmaceutica liofilizada;y uso del compuesto como antineiplasico y/o antiviral.
CL2011000798A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
WO2009051840A3 (en) Compositions and methods for reducing hepatotoxicity associated with drug administration
WO2007101710A8 (en) Use of inhibitors of scavenger receptor class proteins for the treatment of infectious diseases
ECSP088889A (es) Forma nueva de administración de racecadotril
CL2008000610A1 (es) Composicion en forma de dosificacion transdermica o transmucosa que comprende una relacion en peso de buprenorfina a naloxona entre 2,1:1 y 8:1, util para el tratamiento del dolor.
ECSP109960A (es) Gel conteniendo pirfenidona
BRPI0816798A2 (pt) composto, composição farmacêutica, métodos para inibir a ação do glicogênio sintase cinase-3, e para tratar, prevenir ou melhorar uma doença, uso de um composto, e, artigo de fabricação
AR081082A1 (es) Composiciones organicas para tratar enfermedades relacionadas con beta-enac
CL2007003251A1 (es) Compuestos derivados de 1h-pirazoles sustituidos, inhibidores de reacciones catalizadas por una quinasa; su procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; uso de los compuestos principales, utiles en el tratamiento del cancer.
CL2009001841A1 (es) Uso de una composición de liberación sostenida de 4-aminopiridina para preparar un medicamento útil para tratar esclerosis multiple en un sujeto.
PA8784901A1 (es) Utilizacion de un antagonista par1 en el tratamiento de la fibrilacion atrial
AR058361A1 (es) Composiciones lifolizadas de un compuesto de triazolopirimidina
CL2008000607A1 (es) Composicion analgesica en forma de dosificacion parenteral unitaria o en una forma de dosificacion unitaria adecuada para una administracion por la mucosa o la dermis que comprende buprenorfina y nalmefeno, util para el tratamiento del dolor.
AR065085A1 (es) Metodo para tratamiento prolongado del acne vulgaris
HN2011000661A (es) Composicion farmaceutica para el uso en el tratamiento de infecciones de transmision sexual

Legal Events

Date Code Title Description
FB Suspension of granting procedure